Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Leases (2019 - 2022)

Rhythm Pharmaceuticals (RYTM) has disclosed Capital Leases for 4 consecutive years, with $1.8 million as the latest value for Q1 2022.

  • On a quarterly basis, Capital Leases fell 25.98% to $1.8 million in Q1 2022 year-over-year; TTM through Mar 2022 was $1.8 million, a 25.98% decrease, with the full-year FY2021 number at $1.9 million, changed N/A from a year prior.
  • Capital Leases was $1.8 million for Q1 2022 at Rhythm Pharmaceuticals, down from $1.9 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $3.4 million in Q1 2019 to a low of $1.8 million in Q1 2022.
  • A 4-year average of $2.6 million and a median of $2.7 million in 2020 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: decreased 15.1% in 2020, then fell 25.98% in 2022.
  • Rhythm Pharmaceuticals' Capital Leases stood at $3.1 million in 2019, then decreased by 12.77% to $2.7 million in 2020, then decreased by 27.75% to $1.9 million in 2021, then decreased by 8.43% to $1.8 million in 2022.
  • Per Business Quant, the three most recent readings for RYTM's Capital Leases are $1.8 million (Q1 2022), $1.9 million (Q4 2021), and $2.1 million (Q3 2021).